ustekinumabupadacitinibUpaIL-22Ulcerative Colitis
… and extracellular matrix (ECM) dysfunction, is associated with ustekinumab and anti-TNF resistance (Pavlidis et al. 2022). Its receptor is…
35articles mentioning drugs
132drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Ustekinumab ×
Ustekinumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Ustekinumab
35 articles · page 3 of 398.2%
AdalimumabTofacitinibGolimumabInfliximabVedolizumabUstekinumabulcerative colitisIBDIBD-UCrohn’s disease+1 more
…e primary outcome was the association between time to first AT (Adalimumab, Golimumab, Infliximab, Ustekinumab, Vedolizumab or Tofacitinib…
Upadacitinibustekinumabulcerative colitisCrohn’s diseaseAm J GastroenterolInflammatory Bowel Disease
…Introduction Upadacitinib is an oral, selective Janus Kinase 1 (JAK1) inhibitor approved …
ustekinumabvedolizumabadalimumabinfliximabInflammatory Bowel Diseaseulcerative colitisCrohn’s diseasechronic diseaseBMC Health Services ResearchNHS+1 more
…uired minor adjustment. Templates of moderate duration included ustekinumab, vedolizumab, and adalimumab counselling, with completion times…
89.1%
ustekinumabUBUOCrohn’s diseaseplaque psoriasisactive psoriatic arthritisNational Health Service
…Background and Importance The introduction of the ustekinumab biosimilar (UB) offers a new opportunity for cost savings for h…
ustekinumabvedolizumabVDZUSTinflammatory bowel diseaseulcerative colitisCrohn’s diseaseThe Medical Research Ethics CommitteeDanish Medicines Agency
…Introduction Biologic therapies, such as vedolizumab (VDZ) and ustekinumab (UST), offer effective treatment options for inflammatory bowel…
tofacitinibUstekinumabvedolizumabrisankizumabinfliximabadalimumabulcerative colitisIBDinflammatory bowel diseaseCrohn’s disease+4 more
… led to 43.2% clinical remission in an Emirati CD cohort, while tofacitinib achieved clinical remission rates of 56.4% and 61.1% at 52 week…
vedolizumabustekinumabIBDinflammatory bowel diseaseIMIDs
… non-overlapping pathways (eg, anti-tumour necrosis factor with vedolizumab or ustekinumab; Janus Kinase (JAK) inhibitors with gut-selectiv…
infliximabtofacitinibustekinumabgolimumabrituximabsarilumabefzofitimodadalimumabefzofitimobanakinra+1 more
…ngle-arm trials. Fourteen studies evaluated biologic therapies: infliximab (n=5), adalimumab (n=2), etanercept (n=2), golimumab (n=1), rit…
AzathioprineUstekinumabUpadacitinibRisankizumabadalimumabVedolimumabinfliximabUlcerative colitisCrohn’s disease
…dalimumab,50% Vedolimumab,66%(n=4) had Ustekinumab,66%(n=4) had Azathioprine. All patients received UPA as monotherapy.UPA induction was adm…
UpadacitinibvedolizumabinfliximabadalimumabustekinumabUPAulcerative colitisCrohn’s diseaseUC
…Upadacitinib (UPA) is a novel orally administered small molecule drug that w…